Clinical Implications of Updated Data from EHA 2024
Key opinion leaders evaluate the clinical implications of updated data presented at EHA 2024, interpreting how these findings may influence future treatment strategies in multiple myeloma.
Video content above is prompted by the following:
- What Is your current strategy and treatment option for maintenance therapy in NDMM for transplant eligible??
- Please share your thoughts on the updated data from CASSOPEIA. (Moreau P et al. EHA 2024, Abstract S204)
- How does the data impact frontline treatment for transplant eligible NDMM?
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
